Rebrands often look like pure design projects from the outside. A new logo. A fresher color palette. A website that finally feels like this decade.

Especially in science-driven companies, it’s easy to dismiss that as make-up. “We don’t need branding, we need data.” Or: “We’ll think about this after Series A.”

But if you’ve ever been through a real rebrand, you know that the uncomfortable part has nothing to do with picking typefaces.

Branding isn’t make-up, and it certainly isn’t going to “make up” for poor business strategy. You can put a beautiful visual system on top of a fuzzy story, but it will still be fuzzy — just in higher resolution.

You can’t design your way out of strategic fuzziness.

If the strategy is vague, the brand will be vague — no matter how expensive the design work was.

1. Where the real work of rebranding lives

The quiet truth is that most of the rebrand happens before any graphic designer open Illustrator or Photoshop.

Behind every moodboard and logo route, there’s a string of uncomfortable conversations:

• What do we actually do?

• Who do we serve first?

• What are we not?

These are business questions long before they’re design questions.

In biotech, the science is usually clearer than the story. Teams know the mechanism, the models, the data. But if you ask three people to explain the company in one sentence, you get three different answers. One leads with the platform, one with a flagship program, one with impact on patients.

A rebrand simply makes that misalignment visible. It forces you to look at the gap between how you talk internally and what the outside world sees.

2. The questions a rebrand forces you to answer

When I work with biotech teams, we spend a lot of time in what looks, from a distance, like semantics. It isn’t.

What do we really do?

Not just “we’re a platform for X”, but: what problem are we solving in the real world? Are we primarily a technology enabler, a drug developer, a tool, an infrastructure layer? If someone introduced you on stage in one sentence, what would you want them to say?

For whom are we doing it?

Is your first audience pharma partners, biotech R&D leaders, clinicians, regulators, or investors? “For everyone” is not a strategy. The way you frame your story for a pharma BD lead is not the same as for a VC.

Why now?

What changed in the science, the regulation, the market or the tooling that makes your approach urgent and plausible today? Why is this not just a clever idea but the right idea at the right moment?

What are we not?

This is the question most teams avoid. Are you not a CRO, even if you sometimes look like one from the outside? Are you not a consultancy, even if you have early service revenue? Are you willing to say no to certain types of work because they pull you away from where you’re really going?

These questions sound abstract, but they drive very concrete decisions later: how boldly you talk about your platform, how you structure your deck, which case studies you show first, even which conferences you prioritise.

3. Why scientists often mistrust branding

Many scientists I work with are understandably wary of “branding”. They’ve seen fluffy decks full of slogans. They don’t want to be the company that promises to cure everything with AI and a gradient background.

Their fear is that branding will distort the science.

Done badly, it does.

But done well, branding does the opposite: it forces honesty. It exposes contradictions between what leadership says in fundraising meetings, what the website claims, and what the research team believes internally.

A serious rebrand is not decoration. It’s a structured way of asking:

“Are we willing to stand behind this story, everywhere, not just in one slide we like?”

That’s why rebranding can feel uncomfortable. It flushes out unresolved strategic debates: which indication first, which business model, which kind of company you’re building in the long run.

4. The unexpected outcome: a clearer company, not just a clearer logo

By the time the new logo files arrive, something more important has usually happened.

Leadership has aligned around a simple, shared articulation of what the company is, a sharper view of who they’re really talking to, and a more honest sense of what they will — and will not — do.

Once that snaps into place, decisions far beyond “design” become easier. It’s clearer which projects to say no to. Fundraising decks start to sound consistent no matter who presents. New hires understand the company faster and speak about it with more confidence.

The visual identity is just the visible tip of all that thinking. It makes the new story easy to recognise and repeat — but the real value happened earlier, when you were forced to decide.

5. When a rebrand is worth doing

Not every biotech needs a full rebrand right now. But if you recognise yourself in some of these situations, it might be time to look beyond quick fixes:

• The company has changed, but internally you’re still telling the “spin-out from X lab” story.

• The deck, website and LinkedIn all feel like they belong to slightly different companies.

• You’re heading into a serious funding or partnership milestone and feel a little embarrassed by your current materials.

If any of that resonates, treat rebranding not as a makeover, but as an excuse to get brutally clear on the business.

The hidden bonus is that once that clarity is in place, design stops being subjective decoration. It becomes a very precise tool to make your hard-won story visible.